Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral azacitidine maintenance versus placebo in older adults with acute myeloid leukemia in first remission
2012-003457-28Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of azacitidine in acute myeloid leukemia (AML), sponsored by Celgene Corporation. Started Nov 2012; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2012-003457-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003457-28.